Pfizer Just Reassured Investors, but Is the Stock a Buy?

Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (NYSE: PFE) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual.But does that make the stock a buy, or is there reason to be cautious? Let's dig into the details here and make a judgment.To begin, let's compare the new outlook issued by management for 2025 with its recent performance to get a sense of how significant the coming 12 months will be for shareholders.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool